This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stanley, W. C. Search for Related Content PubMed PubMed Citation Articles by Stanley, W. C. Social Bookmarking                         What's this?

Myocardial Energy Metabolism During Ischemia and the Mechanisms of Metabolic Therapies

Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, OH

The primary effect of ischemia is reduced aerobic adenosine triphosphate (ATP) formation in mitochondria. This triggers accelerated glycolysis and reduced cell pH, Ca²⁺ accumulation, K⁺ efflux, adenosine formation, and the clinical signs of ischemia: chest pain and a shift in the ST segment. Traditional therapies for angina are aimed at either decreasing the need for ATP by suppressing heart rate, blood pressure, and cardiac contractility, or at increasing oxygen delivery to the mitochondria, or both. An additional approach to treating angina is to suppress myocardial fatty acid oxidation, increase pyruvate oxidation, and reduce anaerobic glycolysis. High fatty acid levels result in oxygen wasting and inhibit the oxidation of pyruvate in the mitochondria. In experimental models, the partial inhibition of myocardial fatty acid oxidation with agents such as oxfenicine, ranolazine, and trimetazidine stimulates glucose oxidation and reduces lactate production during ischemia. Clinical studies demonstrate that this approach is as effective as traditional hemodynamic therapies at improving exercise tolerance and reducing the frequency of angina. Moreover, because these agents do not suppress heart rate, blood pressure, or contractility, they are effective as add-on therapy to Ca²⁺-channel and ß-adrenergic receptor antagonists.

Key Words: angina • fatty acids • glucose • lactate • mitochondrial • ranolazine

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 9, No. 1 suppl, S31-S45 (2004)
DOI: 10.1177/107424840400900104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. G. Camici and O. E. Rimoldi The Clinical Value of Myocardial Blood Flow Measurement J. Nucl. Med., July 1, 2009; 50(7): 1076 - 1087. [Abstract] [Full Text] [PDF]

				L Belardinelli, J C Shryock, and H Fraser Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine Heart, July 1, 2006; 92(suppl_4): iv6 - iv14. [Abstract] [Full Text] [PDF]

				D. Meng, L. Feng, X.-J. Chen, D. Yang, and J.-N. Zhang Trimetazidine improved Ca2+ handling in isoprenalinemediated myocardial injury of rats Exp Physiol, May 1, 2006; 91(3): 591 - 601. [Abstract] [Full Text] [PDF]